Prior to founding 5AM in 2002, Andrew was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Andrew was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team.

Dr. Beam has led venture capital investments in more than 25 life science and technology companies in the areas of therapeutics, enabling technologies, and diagnostics and also supports a number of strategic corporate initiatives. She supports Alexandria’s west coast operations by providing scientific expertise and insights on the life science and technology sectors. She is responsible for venture investment, business development, and tenant underwriting in Alexandria’s San Francisco Bay Area and Seattle cluster locations through the company’s strategic venture investment arm, Alexandria Venture Investments. Dr. Beam represents Alexandria as a Board Observer for DiCE Molecules, BioGraph 55, and TwinStrand Biosciences.

Prior to joining Alexandria, Dr. Beam was Vice President at Square 1 Bank, where she worked closely with early-stage, venture-backed life science and technology companies and venture capitalists to structure, underwrite, and monitor debt transactions. She earned her Doctor of Philosophy degree in Biomedical Engineering from Northwestern University and her Bachelor of Science degree in Chemical Engineering from Stanford University. Dr. Beam’s research and publications have focused on the fields of protein misfolding, neurodegenerative disease, biochemistry, and florescence-based imaging techniques.

Since joining Pfizer Ventures, the venture capital arm of Pfizer Inc., in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson). Bill currently also serves on the board of directors of NeuMoDx Molecular, Novocure, and RefleXion Medical and as a board observer of Epic Sciences, HD Biosciences (Shanghai, China), M2S, and Nodality. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Bill received a BA in chemistry from Whitman College and an MBA from Columbia Business School.

Mark Gallop joined 5AM Ventures as an Executive-in-Residence in June 2018, and consults with emerging biotechnology companies on drug discovery technologies and strategies, with an emphasis on neuroscience, oncology, gastrointestinal disorders and prodrug design.

From 2012 to 2017 he served as the founding Chief Scientific Officer at Nurix, Inc., a venture-backed discovery company formed to explore drug development targeting ubiquitin ligase enzymes, with therapeutic applications spanning oncology, immunology, inflammation and immuno-oncology. Prior to joining Nurix, he was Senior Vice President of Research and XenoPort, Inc., a company he co-founded in 1999 with the mission of improving the clinical utility of medicines by exploiting active transport mechanisms to optimize pharmacokinetic properties of drugs. While at XenoPort, his team discovered Horizant™, a prodrug of gabapentin that was approved by the FDA in 2011 and the MHW in Japan in 2012 for the treatment of restless legs syndrome and neuropathic pain. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax.

He is recognized as an early pioneer and international expert in solid-phase combinatorial chemistry and was a recipient of the ACROS award of the Belgian Organic Synthesis Symposium in 1996 for his outstanding contributions to this field. He is an inventor on more than 100 issued or pending U.S., and PCT patents and an author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry.

After undergraduate studies in New Zealand, he obtained his Ph.D. degrees in inorganic chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

Ariel G. Notcovich is an accomplished life science executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his graduate studies in Physics at the Technion-Israel Institute of Technology and served as its CTO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories. Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.